Fiber fix? study tests if a simple supplement boosts arthritis Drug's power

NCT ID NCT05812157

Completed Disease control Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding a daily fiber supplement (inulin) to standard anti-IL-17 therapy could improve gut bacteria balance and treatment response in 76 adults with axial spondyloarthritis. Participants took either fiber or a placebo powder for three months. The main goal was to see if fiber increased beneficial gut bacteria. If successful, this simple addition might help patients get more out of their medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inulin (Fibruline) fiber supplement
What this could lead to: If it works, this could point toward a simple dietary addition that helps people with axial spondyloarthritis respond better to their anti-IL-17 medication.
What could go wrong: This is a small, early-stage study focused on gut bacteria changes, not direct symptom improvement. The fiber supplement may not meaningfully affect disease activity or treatment outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AXIAL SPONDYLOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Axial Spondyloarthritis Dysbiosis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AXIAL SPONDYLOARTHRITIS

Contacts and locations

Locations

Montpellier University Hospital

Montpellier, Hérault, 34000, France
Nîmes University Hospital

Nîmes, Gard, 30029, France
Tours Regional University Hospital (Bretonneau)

Tours, Indre-et-Loire, 37032, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.